COVID-19
NanoViricides' Experimental Antiviral Drug May Help Lower Risk of Metastatic Cancer Recurrence After Viral Infections
Researchers have discovered that inflammation caused by infections such as COVID-19 and influenza can reactivate dormant cancer cells, leading to the resurgence of metastatic disease. However, a new experimental antiviral drug, NV-387, may hold the key to mitigating this risk. Developed by NanoViricides, NV-387 has shown promise in preclinical studies